GBIM:OTCMKTS
GlobeImmune Inc
US$0.00010
0.00%
(0.00) 1 天
9月29日, GMT-4 15:48:52 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 GBIM 生成关键数据洞见…
市值
580.00
平均成交量
1740.00
成交量
0.00
52 周最高价
US$0.04
52 周最低价
US$0.00
流通股数
575.20万
员工人数
22
市值
580.00
平均成交量
1740.00
成交量
0.00
52 周最高价
US$0.04
52 周最低价
US$0.00
流通股数
575.20万
员工人数
22
新闻报道
来自网络来源和新闻合作伙伴
Traders Union
·
20小时前
投资者撤离科技股，标普500指数期货上涨
资料
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc简介